COMPETITIVE MOLECULE NOTE | INDIA | MONTELUKAST

PHARMA

MOLECULE AND FORMULATION MARKETING PLAYBOOK

THE NEXT SHARE SHIFT IN MONTELUKAST WILL NOT COME FROM ANOTHER NIGHT-TIME TABLET REMINDER

A clinic-centred appropriate-use and monitored-continuation playbook for brands defending leadership, attacking leadership, or taking selective share

Publication No. 2026 05 91

Shared with the leadership teams of major competing montelukast brands in India

MONTELUKAST

Montelukast is familiar, widely prescribed, easy to explain, and heavily competed. Public Indian drug-brand directories list 110 montelukast brands, which makes the molecule commercially large but structurally vulnerable to substitution, habit-led prescribing, and weak brand distinction. (Medindia)

But montelukast now sits in a different global safety and guideline environment. GINA 2025 notes that leukotriene receptor antagonists, including montelukast, are less effective than daily inhaled corticosteroids, particularly for preventing asthma exacerbations, and that montelukast is associated with serious mental-health-effect concerns. The FDA also requires a boxed warning for serious neuropsychiatric events and recommends that montelukast for allergic rhinitis be reserved for patients who have inadequate response or intolerance to alternatives. (U.S. Food and Drug Administration)

That changes the commercial game. The next winning montelukast brand will not be the brand that makes montelukast look casual. It will be the brand that helps doctors prescribe it more deliberately, counsel it more clearly, monitor it more responsibly, and review continuation more systematically.

This publication outlines a molecule-specific clinic workflow model for montelukast. It is built for three brand positions: leaders defending default share, challengers trying to reframe the molecule, and mid-tier brands seeking selective share gain.

The opportunity is molecule-wide. The first brand to own the responsible-use workflow will force the rest of the market to respond.

EXECUTIVE SUMMARY

Montelukast has become too easy to prescribe. That is the problem. For years, the molecule's commercial strength came from convenience: once-daily oral dosing, familiar use in asthma and allergic rhinitis contexts, frequent use in paediatric and family practice, and easy patient acceptance. But convenience has created complacency.

In many clinics, montelukast has drifted into a casual nightly-tablet habit. That creates four commercial problems:

First, the brand decision becomes weak. If the molecule is treated casually, brands inside it become substitutable.

Second, continuation becomes poorly reviewed. Patients may remain on therapy because nobody created a stop, continue, or reassess moment.

Third, counselling becomes inconsistent. The doctor may prescribe correctly, but the patient or parent may not understand what to watch for, when to return, or why the tablet should not be continued indefinitely without review.

Fourth, the molecule carries a sharper safety conversation than many brands are prepared to handle. The FDA specifically advises counselling all patients about mental-health side effects and monitoring patients treated with montelukast for neuropsychiatric symptoms. (U.S. Food and Drug Administration)

So the strategic opening is clear. Montelukast does not need another convenience campaign.

It needs one brand to build the first serious appropriate-use and monitored-continuation system

THE MARKET REALITY

Montelukast brands are competing in a crowded, high-frequency, habit-led environment.

The molecule is easy to remember. That sounds like an advantage. In reality, it weakens brand defence. When doctors and patients think in broad molecule shorthand - "give montelukast," "night tablet," "allergy-asthma tablet" - the brand can disappear inside the category. This is especially dangerous because montelukast is not a molecule where responsible brands should overclaim. GINA frames LTRA use as having a narrower role than inhaled corticosteroid-led controller care in asthma, and the FDA has placed a strong counselling and risk-benefit frame around montelukast, especially in allergic rhinitis. (U.S. Food and Drug Administration)

This creates a new type of competitive opportunity.

A brand that still sells montelukast as "easy, convenient, nightly relief" stays trapped in the old market.

A brand that helps clinics answer the harder questions can own the new market:

Who is the right patient?
Was the patient counselled?
What should the family watch for?
When should continuation be reviewed?
When should the clinic re-enter?

That is the new battleground.

THE DRIFT DEFINITION

MONTELUKAST AUTOPILOT DRIFT

The drift in montelukast is not lack of molecule awareness. The drift is uncontrolled continuation without enough structured review.

The pattern is familiar:

allergy / wheeze / asthma-overlap complaint → montelukast written → patient accepts easily → symptoms fluctuate → tablet continues → safety counselling may fade → review moment is missed → brand choice remains weak

This creates five leaks.

1. Indication drift
Montelukast may be used in situations where the clinical rationale is not strongly reinforced for the patient or parent. The patient remembers the tablet, not the reason.

2. Counselling drift
The doctor may have made an appropriate decision, but the family may not remember what side effects to watch for or when to contact the clinic.

3. Continuation drift
A once-daily tablet can become a habit. If nobody creates a review point, continuation becomes inertia.

4. Brand drift
Once the molecule becomes a routine tablet, the brand is easy to replace at the prescription desk or pharmacy.

5. Trust drift
Doctors who want to be careful may become less receptive to brands that appear to push convenience without responsibility.

The next brand advantage will come from solving this drift, not from amplifying it.

The Real Commercial Problem

PROBLEM FRAMEWORK

MOST MONTELUKAST BRANDS ARE SELLING CONVENIENCE.
THE NEXT WINNER WILL SELL CONTROL.

The old montelukast playbook says:

- once daily
- convenient
- good acceptance
- useful in allergy and asthma contexts
- remember our brand

That is now too thin. The more credible brand conversation is:

“Doctor, when you decide montelukast is appropriate, our brand helps your clinic counsel, monitor, and review that decision properly.”

That is a different sales call. It respects the doctor’s clinical authority. It does not push the molecule indiscriminately. It gives the clinic a practical workflow. And it makes the sponsoring brand feel like a partner in disciplined care, not just another tablet brand asking for recall.

“DOCTOR, WHEN YOU DECIDE MONTELUKAST IS APPROPRIATE, OUR BRAND HELPS YOUR CLINIC COUNSEL, MONITOR, AND REVIEW THAT DECISION PROPERLY.”

THE BEHAVIOURAL MOMENT MAP

THE MOMENTS THAT MATTER

Montelukast share is won or lost across six moments.

Moment 1: Symptom pattern recognition

The patient presents with allergic rhinitis symptoms, wheeze, cough, recurrent night symptoms, exercise symptoms, seasonal recurrence, or asthma-allergy overlap.

The clinic must first decide whether this is an allergy symptom problem, asthma control problem, rhinitis problem, poor inhaler adherence problem, trigger problem, or something else. This is not a brand moment yet. It is a clinical sorting moment.

IF THE CLINIC OWNS THE RE-ENTRY WORKFLOW, THE BRAND REMAINS LINKED TO DISCIPLINED CARE.

Moment 2: Appropriate-use decision

The doctor decides whether montelukast fits this patient's situation. This is the decisive moment. A responsible brand should not try to bypass it.

The brand opportunity starts only after the doctor has decided that montelukast is appropriate.

Moment 3: Counselling at prescription

This is where most brands are weak. Patients and parents need to understand:

- why the doctor prescribed it
- that it should be taken only as advised
- what symptoms or behaviour changes should trigger contact with the clinic
- when follow-up is expected
- why continuation should not become automatic

Moment 4: Early-use check

The patient starts treatment. Symptoms may improve, persist, fluctuate, or appear unrelated. Sleep, mood, irritability, dreams, behaviour, or other concerns may emerge.

Most brands are absent here.

Moment 5: Review decision

The clinic decides whether to continue, stop, change, escalate, or re-evaluate.

This is the under-owned commercial moment. The brand that helps clinics create this moment can gain trust and retention.

Moment 6: Seasonal / recurrent re-entry

Allergy and wheeze symptoms recur. The patient may restart old tablets, ask the pharmacist, or return to clinic.

If the clinic owns the re-entry workflow, the brand remains linked to disciplined care.

PRESCRIBE DELIBERATELY.
COUNSEL CLEARLY. REVIEW ON TIME.

THE CLINIC-CENTRED SOLUTION FRAMEWORK

A CLINIC-CENTRED RESPONSIBLE-USE WORKFLOW FOR MONTELUKAST

The objective is not to make montelukast look like a casual nightly habit.

The objective is to make the sponsoring brand the doctor's preferred montelukast brand when montelukast is clinically justified, by helping the clinic manage counselling, early monitoring, and continuation review.

This is the core proposition:

When you decide montelukast is appropriate, this brand helps your clinic make that decision safer, clearer, and more reviewable.

That is the brand weapon.

THE SOLUTION CONCEPT

THE SERVICE ARCHITECTURE



MODULE 1: CLINIC-BRANDED ALLERGY & WHEEZE REVIEW LINK

A clinic-branded digital link shared by the clinic through QR code, WhatsApp, or printed prescription insert.

It is patient-facing but not promotional. It does not show the pharma brand. It does not recommend montelukast. It does not tell patients to start, stop, restart, or change treatment. It does not diagnose asthma or allergic rhinitis.

It does four things:

1. Reinforces the clinic's instructions.
2. Explains why follow-up matters.
3. Captures early concern signals.
4. Prompts the patient or caregiver to contact the clinic if review is needed.

Suggested patient-facing names:

My Clinic Allergy & Wheeze Check
Doctor's Allergy Review Link
Clinic Night-Symptom & Allergy Follow-up

The naming must sound like clinic care, not pharmaceutical promotion.

MODULE 2: DOCTOR-FACING MONTELUKAST FIT CUE

This is an academy-backed, doctor-facing decision cue.

It helps the doctor structure the conversation around:

- where montelukast may fit
- when alternatives should be considered
- how to explain the role of the medicine
- what safety signals patients and caregivers should know
- when review should happen
- when continuation should not be automatic

The sponsoring brand appears only in the doctor-facing execution layer, after the doctor has made the molecule decision.

The key line: "For patients in whom you choose montelukast, our brand supports a monitored-use workflow."

MODULE 3: COUNSELLING CONFIRMATION

At prescription, the clinic shares a short counselling checklist.

The patient or caregiver confirms:

- I understand why the medicine was prescribed.
- I will take it only as advised.
- I will not restart or continue it indefinitely without review.
- I know which changes in sleep, mood, behaviour, agitation, dreams, irritability, or other concerns should be discussed with the clinic.
- I know when my follow-up is due.

This is not medico-legal theatre. It is clinic trust infrastructure.

MODULE 4: DAY-7 EARLY-USE CHECK

The clinic-branded link asks:

- Are symptoms improving?
- Is the medicine being taken as advised?
- Has the patient missed doses?
- Any new sleep disturbance?
- Any mood or behaviour change?
- Any unusual irritability, agitation, nightmares, anxiety, or other caregiver concern?
- Does the patient need clinic review?

The system does not make decisions. It flags the clinic.

MODULE 5: DAY-30 CONTINUATION REVIEW

This is the commercial hinge. The system asks:

- Is the patient still using the medicine?
- Was continuation advised by the doctor?
- Are symptoms controlled?
- Is there recurrence after stopping?
- Is the patient also using inhalers, nasal sprays, antihistamines, or other medicines?
- Does the clinic need to review the treatment plan?

This creates a review point where the market currently has inertia.

"FOR PATIENTS IN WHOM YOU CHOOSE MONTELUKAST, OUR BRAND SUPPORTS A MONITORED-USE WORKFLOW."

MODULE 6: SEASONAL RE-ENTRY LOOP

For allergy season or recurrent wheeze patterns, the same clinic link can be reused.

The patient is guided back to the clinic rather than self-restarting old medicines.

The message is simple:

Do not restart previous allergy or asthma medicines without checking with your doctor. Use this link to request clinic review.

Again, no brand appears. The clinic owns the patient relationship. The sponsoring brand underwrites the workflow. That is why the doctor trusts it.



DOCTOR EDUCATION INFRASTRUCTURE

The academic layer must avoid old-style molecule pushing. It should help doctors manage the practical problems around montelukast.

Six-month academy-backed micro-education sequence

MONTH 1

- *Montelukast is not a casual continuation drug*

Core message: appropriate selection and review matter more than habit.

MONTH 2

- *How to counsel patients and parents before starting montelukast*

Core message: the counselling moment is part of responsible prescribing.

MONTH 3

- *Allergic rhinitis, asthma overlap, and the risk of over-simplifying the night tablet*

Core message: symptom overlap should not become molecule autopilot.

MONTH 4

- *What to ask at the first follow-up*

Core message: symptom response and safety signals must both be reviewed.

MONTH 5

- *When to continue, stop, switch, or reassess*

Core message: continuation needs a decision, not inertia.

MONTH 6

- *Building a monitored-use routine inside a busy clinic*

Core message: the workflow should reduce workload, not add burden.

Each module should be short: one page, English, academy-certified, rep-delivered in under five minutes.


STRATEGIC VARIANTS
BY BRAND POSITION

IF YOU ARE THE LEADER

DEFEND LEADERSHIP BEFORE RESPONSIBILITY BECOMES THE CHALLENGER'S WEAPON

Your current advantage is familiarity. That is useful, but fragile.

If a challenger becomes the first montelukast brand to own the monitored-use workflow, your leadership starts to look old-market. You may still be remembered, but another brand will be seen as more responsible, more useful, and more aligned with the doctor's risk environment.

Your play:

- occupy the responsible-use system first
- make your brand the clinic's monitored montelukast default
- protect continuation through structured review
- create doctor dependence on your workflow
- make competitors look like they are still selling convenience

The leader's best move is to turn scale into discipline.

IF YOU ARE THE CHALLENGER

The leader owns memory. You can own the new standard.

Do not fight on “once daily” or “trusted molecule” alone. That battle favours incumbents.

Fight on the category’s exposed point: Montelukast needs better counselling and review. We have built the clinic system for it.

Your play:

- install the monitored-use workflow in selected clinics
- give doctors a reason to reassess brand choice
- attach your brand to appropriate-use confidence
- convert responsibility into preference

This is how a challenger reframes a crowded molecule.

DO NOT OUTSHOUT THE LEADER. MAKE THE LEADER LOOK CASUAL.

IF YOU ARE A SHARE-GAIN BRAND

DO NOT TRY TO OWN ALL MONTELUKAST. OWN A REVIEWABLE WEDGE.

Choose a segment where the workflow matters most:

- paediatric-heavy clinics
- family physicians managing recurrent allergy and wheeze
- seasonal allergy clusters
- clinics with high repeat montelukast use
- semi-urban markets where pharmacist influence is high
- doctors who want better patient counselling but lack time

Your play:

- install in 100–300 clinics
- measure workflow use
- create doctor dependence
- improve brand-of-use inside activated clinics
- expand only after the wedge proves repeatable

This is not a national reminder campaign. It is a local default-capture system.

FIELD FORCE STORYLINE

The old rep call says:

“Doctor, please remember our montelukast brand.”

The new call says:

“Doctor, montelukast should not become an unreviewed nightly habit. We have built a clinic-branded counselling and review system that helps your clinic explain use, capture early concerns, and review continuation. When you decide montelukast is appropriate, our brand supports that responsible-use workflow.”

That is a stronger call.

It gives the doctor a reason to listen. It gives the rep a reason to return. It gives the brand a position competitors cannot erase with another reminder card.

IMPLEMENTATION MODULES

PHASE 1: SEGMENT SELECTION

Identify the strongest use environments:

- paediatric / family practice
- allergy-heavy GP clinics
- asthma-allergy overlap clinics
- high seasonal rhinitis markets
- doctors with high repeat-prescription load

Classify clinics by likely drift:

- counselling drift
- continuation drift
- safety-monitoring drift
- self-restart drift
- brand-substitution drift



PHASE 2: CLINIC INSTALLATION

For each clinic:

- configure clinic name and branding
- generate clinic-specific Allergy & Wheeze Review Link
- train staff to share the link
- give doctor the Montelukast Fit Cue
- place follow-up QR at prescription desk
- set day-7 and day-30 review logic

PHASE 3: PATIENT JOURNEY ACTIVATION

The clinic shares the link only after consultation. The link reinforces:

- follow clinic instructions
- do not self-restart
- report concerns
- complete review check
- return to clinic when prompted

PHASE 4: MONTHLY ACADEMIC REINFORCEMENT

Field reps deliver one academy-backed micro-topic each month. This converts a one-time service into a recurring doctor relationship.

PHASE 5: MEASUREMENT AND SCALE

Use clinic-level dashboards to identify:

- active clinics
- repeat users
- patient completion
- review triggers
- brand movement
- regions ready for scale-up

MEASUREMENT MODEL

CLINIC ACTIVATION METRICS

- clinics onboarded
- active clinics per week
- review links shared
- repeat link usage
- staff adoption

PATIENT WORKFLOW METRICS

- counselling confirmation completions
- day-7 check completions
- day-30 review completions
- safety-concern flags
- self-restart signals
- continuation-without-review signals

DOCTOR ENGAGEMENT METRICS

- monthly education completion
- repeat doctor discussion
- continued use after first month
- doctor willingness to expand usage

BRAND OUTCOME PROXIES

- brand-of-use change in activated clinics
- same-brand continuation proxy
- reduction in substitution signals
- repeat prescription rate in review-linked patients
- sales change versus matched control clinics

TRUST METRICS

- doctor perception of brand as responsible
- willingness to recommend the clinic link
- preference for brand in patients where montelukast is appropriate

The best outcome is not simply "more montelukast." The better claim is: more controlled, more reviewable, more trusted montelukast use where the doctor has already chosen the molecule.

COMPLIANCE AND TRUST GUARDRAILS

THIS MOLECULE NEEDS TIGHT GUARDRAILS.

PATIENT-FACING LAYER

- no brand name
- no molecule promotion
- no claims of superiority
- no instruction to start, stop, restart, or change medication
- no diagnosis
- no promise of symptom control
- no direct-to-patient brand retargeting

DOCTOR-FACING LAYER

- academy-backed
- evidence-aligned
- risk-benefit framed
- clear that physician judgment governs use
- brand appears only after the doctor has chosen montelukast

DATA LAYER

- no unnecessary patient-identifiable data
- consent-based communication
- encrypted event IDs
- clinic-level reporting
- no promotional patient database

The principle is simple:

The brand wins because doctors trust the workflow, not because patients are pushed.

FIRST-MOVER ADVANTAGE

In montelukast, first mover advantage is unusually strong because the molecule has a visible safety and review gap.

The first brand to install a monitored-use workflow gets:

- first claim on responsible-use infrastructure
- first association with counselling discipline
- first clinic habit loop
- first behavioural data around continuation and review
- first opportunity to make competitors look casual

Later entrants can imitate the language.nThey will struggle to displace the workflow once it is installed. That is why this note has been circulated across competing montelukast brand teams. The market will not wait politely while every brand evaluates.

ONE BRAND WILL MOVE FIRST

STRATEGIC OPPORTUNITY & CTA

WWW.INDITECH.CO.IN

Montelukast does not need another reminder campaign. It needs one brand to change the rules.

The old rule was:

make the tablet easy to remember.

The new rule is:

make the prescription safer to counsel, easier to review, and harder to commoditise.

The first brand to build that system will not just compete for recall. It will compete for trust.

The decision for a montelukast brand team is direct:

Will you remain one more brand inside the nightly-tablet habit, or will you become the brand doctors associate with disciplined montelukast use?

EMAIL: Amit@inditech.co.in

INDITECH HEALTH SOLUTIONS

WWW.Inditech.co.in

Publication No. 2026 05 91